Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Abstract excerpt

PURPOSE: Recent studies have demonstrated that short-form Ron (sfRon) kinase drives breast tumor progression and metastasis through robust activation of the PI3K pathway. We reasoned that upfront, concurrent inhibition of sfRon and PI3K might enhance the antitumor effects of Ron kinase inhibitor therapy while also preventing potential therapeutic resistance to tyrosine kinase inhibitors (TKI). EXPERIMENTAL...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Phosphatidylinositol 3-Kinases
• Share to Phosphoinositide-3 Kinase Inhibitors